Sun Yat-sen University — Biomedical Watch V2

Traitements12programmes

Essais5liés

Publications8liées

SourceDBlocale

Traitements

12

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ArtesunateThis is a multi-center, randomized, double-blind, placebo-controlled study. Study subjects are class III, IV, V, III+V, IV+V lupus nephritis patients, according to ISN/RPS 2003 classification of LN, with active lesion needing corticosteroid in combination with immunosuppressant therapy. Subjects who meet the eligibility criteria during screening will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio: 25mg bid artesunate, 50mg bid artesunate or placebo plus standard of care (prednisone plus mycophenolate mofetil ［MMF］) for 6 month.	Lupus	Phase 4	À vérifier	China	À vérifier
DorzagliatinThis study aims to evaluate whether dorzagliatin can improve glycemic homeostasis in patients with type 2 diabetes mellitus (T2DM) complicated by chronic renal insufficiency, and to compare the efficacy of dorzagliatin with linagliptin in improving glycemic control in patients with T2DM and moderate to severe chronic renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<45 mL/min/1.73 m²). This is a prospective, randomized, active-controlled, multicenter clinical study planned to enroll 206 eligible patients. After successful screening, patients will enter a 2-week run-in period consisting of diet and exercise control together with continuous glucose monitoring (CGM). Eligible patients will then be randomized to receive dorzagliatin 75 mg twice daily (BID) or linagliptin 5 mg once daily (QD) on top of background antihyperglycemic therapy. Basal insulin therapy will be standardized to insulin glargine U300 after treatment initiation. The treatment period will last 14 weeks, followed by a 1-week safety follow-up period.	Maladie rénale chronique	Non applicable	À vérifier	China	À vérifier
Intensity-Modulated Radiation TherapyThis pilot phase I/II trial studies the side effects and how well nivolumab and ipilimumab in combination with chemotherapy and radiation therapy work in treating patients with gastric cancer that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Intensity-modulated radiation therapy uses thin beams of radiation of different strengths aimed at the tumor from many angles. This type of radiation therapy may reduce the damage to healthy tissue near the tumor. Giving nivolumab, ipilimumab, chemotherapy and radiation therapy may work better in treating patients with gastric cancer.	Cancer	Phase 2		China	À vérifier
LinagliptinThis study aims to evaluate whether dorzagliatin can improve glycemic homeostasis in patients with type 2 diabetes mellitus (T2DM) complicated by chronic renal insufficiency, and to compare the efficacy of dorzagliatin with linagliptin in improving glycemic control in patients with T2DM and moderate to severe chronic renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<45 mL/min/1.73 m²). This is a prospective, randomized, active-controlled, multicenter clinical study planned to enroll 206 eligible patients. After successful screening, patients will enter a 2-week run-in period consisting of diet and exercise control together with continuous glucose monitoring (CGM). Eligible patients will then be randomized to receive dorzagliatin 75 mg twice daily (BID) or linagliptin 5 mg once daily (QD) on top of background antihyperglycemic therapy. Basal insulin therapy will be standardized to insulin glargine U300 after treatment initiation. The treatment period will last 14 weeks, followed by a 1-week safety follow-up period.	Maladie rénale chronique	Non applicable	À vérifier	China	À vérifier
Megestrol Acetate + Trastuzumab DeruxtecanThis study aims to evaluate whether the combination of Megestrol Acetate at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can effectively prevent and alleviate T-DXd-related fatigue, thereby improving the quality of life for advanced breast cancer patients.	Cancer	Phase 3	Traitement symptomatique	China	À vérifier
pembrolizumab or nivolumab or JS001The inhibition of programmed cell death protein 1 (PD-1) has shown promising antitumor activity in advanced hepatocellular carcinoma (HCC). Unfortunately, less than 20% of HCC have response. The effect of PD-1 blockade and incomplete thermal ablation in patients with advanced HCC is not yet clearly understood. This study aimed to analyze outcomes of advanced HCC treated with anti PD-1 inhibitors in combination with incomplete thermal ablation.	Cancer	Phase 2	À vérifier	China	À vérifier
ToripalimabThe purpose of this study is to determine the safety and efficacy of immunotherapy toripalimab (anti-PD-1 mAb) combined with thermal ablation in patients with Hepatocellular Carcinoma (HCC).	Cancer	Phase 2	À vérifier	China	À vérifier
ArtesunateThis is a multi-center, randomized, double-blind, placebo-controlled study. Study subjects are class III, IV, V, III+V, IV+V lupus nephritis patients, according to ISN/RPS 2003 classification of LN, with active lesion needing corticosteroid in combination with immunosuppressant therapy. Subjects who meet the eligibility criteria during screening will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio: 25mg bid artesunate, 50mg bid artesunate or placebo plus standard of care (prednisone plus mycophenolate mofetil ［MMF］) for 6 month.	Lupus	Phase 4	À vérifier	China	À vérifier
Megestrol Acetate + Trastuzumab DeruxtecanThis study aims to evaluate whether the combination of Megestrol Acetate at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can effectively prevent and alleviate T-DXd-related fatigue, thereby improving the quality of life for advanced breast cancer patients.	Cancer	Phase 3	Traitement symptomatique	China	À vérifier
DorzagliatinThis study aims to evaluate whether dorzagliatin can improve glycemic homeostasis in patients with type 2 diabetes mellitus (T2DM) complicated by chronic renal insufficiency, and to compare the efficacy of dorzagliatin with linagliptin in improving glycemic control in patients with T2DM and moderate to severe chronic renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<45 mL/min/1.73 m²). This is a prospective, randomized, active-controlled, multicenter clinical study planned to enroll 206 eligible patients. After successful screening, patients will enter a 2-week run-in period consisting of diet and exercise control together with continuous glucose monitoring (CGM). Eligible patients will then be randomized to receive dorzagliatin 75 mg twice daily (BID) or linagliptin 5 mg once daily (QD) on top of background antihyperglycemic therapy. Basal insulin therapy will be standardized to insulin glargine U300 after treatment initiation. The treatment period will last 14 weeks, followed by a 1-week safety follow-up period.	Maladie rénale chronique	Non applicable	À vérifier	China	À vérifier
pembrolizumab or nivolumab or JS001The inhibition of programmed cell death protein 1 (PD-1) has shown promising antitumor activity in advanced hepatocellular carcinoma (HCC). Unfortunately, less than 20% of HCC have response. The effect of PD-1 blockade and incomplete thermal ablation in patients with advanced HCC is not yet clearly understood. This study aimed to analyze outcomes of advanced HCC treated with anti PD-1 inhibitors in combination with incomplete thermal ablation.	Cancer	Phase 2	À vérifier	China	À vérifier
ToripalimabThe purpose of this study is to determine the safety and efficacy of immunotherapy toripalimab (anti-PD-1 mAb) combined with thermal ablation in patients with Hepatocellular Carcinoma (HCC).	Cancer	Phase 2	Traitement symptomatique	China	À vérifier

Essais cliniques

5

Molécule	Indication / population	Phase	NCT	Titre	Statut
Toripalimab	Cancer	Phase 2	NCT05975307	BCIRT-01 — Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation	ACTIVE_NOT_RECRUITING
pembrolizumab or nivolumab or JS001	Cancer	Phase 2	NCT03939975	Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC	COMPLETED
Dorzagliatin	Maladie rénale chronique	Non applicable	NCT07786571	Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency	WITHDRAWN
Megestrol Acetate + Trastuzumab Deruxtecan	Cancer	Phase 3	NCT07543536	MEGA-TACT-BC3 — Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer	RECRUITING
Artesunate	Lupus	Phase 4	NCT03214731	AURORA — Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis	UNKNOWN

Publications

8

Molécule	Indication / population	Titre	Journal	Date
Artesunate		Artesunate ameliorates experimental autoimmune uveitis by inhibiting the LCN2-STAT3 axis and suppressing microglial activation.	Redox report : communications in free radical research
Artesunate		Artesunate-loaded bovine serum albumin nanoplatform with metal-polyphenol network coating for ferroptosis-driven breast cancer therapy.	International journal of pharmaceutics: X
Artesunate		Combinations of stem bark powders of Enantia chlorantha and Uvaria chamae showed antimalarial activities in mice.	Journal of ethnopharmacology
Artesunate		Correction: Zhao et al. Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering Integrins. 2025, , 570.	Cells
Artesunate		Integrated Bioinformatics Analysis Identifies FCER1G, IL1R2, and BST1 as Diagnostic Biomarkers and Therapeutic Targets in Sepsis.	Journal of clinical laboratory analysis
Artesunate		Drug repurposing as a promising therapeutic strategy against renal cell carcinoma.	Cancer chemotherapy and pharmacology
Artesunate		Two Cases of Malaria-Associated Acute Respiratory Distress Syndrome and Severe Pulmonary Complications From Plasmodium falciparum in Tanzania.	The American journal of case reports
Artesunate		In situ engineering of a self-healing drug-scaffold hydrogel to block platelet-driven postoperative metastasis.	Biomaterials